Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-117 in advanced solid tumors with PTEN mutations
NCT04770246Phase 1Terminated
- Sponsor
- Taiho Oncology
- Start
- Mar 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of pifusertib in solid tumor (advanced stage) and metastatic solid tumors (4 arms), sponsored by Taiho Oncology. Primary endpoints: Incidence of treatment-emergent adverse events and dose-limiting toxicities at 7 months, Recommended Phase 2 Dose at 7 months and 1 more. Started Mar 2021; status: terminated.
02
Drugs
pifusertib
03
Conditions
solid tumor (advanced stage)metastatic solid tumors
Beyond the preview
Go deeper on NCT04770246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04770246.